Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib Rollover for GS-9820 Subjects
NCT02739360Phase 4Terminated
- Sponsor
- Gilead Sciences
- Start
- May 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of idelalisib in lymphoid malignancies, sponsored by Gilead Sciences. Started May 2016; status: terminated.
02
Drugs
idelalisib
03
Conditions
lymphoid malignancies
Beyond the preview
Go deeper on NCT02739360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02739360.